The Hong Kong stock market's biopharmaceutical sector showed significant divergence today 😔.
WuXi Biologics fell by 3.9%, and CSPC Pharmaceutical Group fell by 4.2%. CROs and traditional pharmaceutical companies are under pressure from short-term valuation due to overseas compliance risk sentiment.
CARsgen Therapeutics-B rose against the trend by 3.7%, reflecting selective capital attention on some innovative drug pipeline targets. Desheng-B remained largely flat.
The overall valuation of Hong Kong-listed pharmaceutical stocks remains relatively low globally, but regulatory uncertainty and geopolitical sensitivity are persistent discount factors. It is necessary to distinguish between systemic sector pressure and individual stock alpha.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
